AC Immune in neurodegenerative diseases collaboration with Biogen

18 April 2016

Swiss biopharma company AC Immune has announced a collaboration with US biotech major Biogen (Nasdaq: BIIB) to develop PET-ligands for two protein targets involved in pathogenesis of neurodegenerative diseases.

The companies will further research, develop and clinically validate an alpha-synuclein PET radioligand that will be used as an imaging biomarker for Parkinson’s disease and related synucleinopathies to develop new disease-modifying therapies.

They will also pursue a new research program to identify and develop novel PET radioligands for TDP-43, a recently identified target of growing interest in the pathogenesis of neurodegenerative diseases such as amyotrophic lateral sclerosis - Lou Gehrig’s disease.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK